Dr. Rudin on Significance of the KEYNOTE-021 in Patients With NSCLC

Video

In Partnership With:

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of KEYNOTE-021.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses the caveats of the KEYNOTE-021 trial.

KEYNOTE-021 cohort G was one arm of a very large trial that enrolled patients with previously untreated metastatic non—small cell lung cancer (NSCLC). That study was the first to look at the role of first-line chemotherapy plus immunotherapy for NSCLC. The results suggested that chemotherapy with immune-oncology drugs was better than chemotherapy alone.

Some of the caveats of the trial are that it was a small trial that was powered to look at survival. The progression-free survival curves seemed to favor the immunotherapy arm, but the trials were really designed with a primary endpoint of response rate. Ultimately, the phase III data need to be seen before it can be established as a standard of care, says Rudin.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,